Brief: OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
29/10/2025 12:59
Oct 29 (Reuters) - OPKO Health Inc OPK.O: OPKO HEALTH’S MODEX THERAPEUTICS ENTERS INTO RESEARCH COLLABORATION WITH REGENERON TO DEVELOP MULTISPECIFIC ANTIBODIES FOR SELECT THERAPEUTIC INDICATIONS OPKO HEALTH - MODEX TO RECEIVE $7 MILLION UPFRONT AND OVER $200 MILLION PER SELECTED MOLECULE OPKO HEALTH - COLLABORATION VALUE POTENTIALLY EXCEEDS $1 BILLION IF SUCCESSFUL OPKO HEALTH - MODEX ELIGIBLE FOR TIERED GLOBAL NET SALES ROYALTIES,UP TO LOW DOUBLE DIGITS AT THE HIGHEST TIER Source text: ID:nGNX9WCYtC Further company coverage: OPK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on OPKO Health
See all newsOpko Health, Inc. Expected To Post A Loss Of 7 Cents A Share: Earnings Preview
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
US RESEARCH ROUNDUP-Bank7, Goldman Sachs, Morgan Stanley
Deals of the day-Mergers and acquisitions
US STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons